Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(2)
•••

Comment by Geisha109on Mar 11, 2025 1:57pm

94 Views

Post# 36488742

RE:RE:RE:RE:RE:RE:Jason Donnville- BNN comment

What is your thought process for a failure in the US? Because the stock sold off?

CPH is an illiquid, relatively unknown stock. Market has sold off, especially small caps. Results coming soon which will provide an update on thir progress integrating the US business.

<< Previous

Bullboard Posts

Next >>

Hydrogen at a crossroads: Plug Power, Pure Hydrogen and Nel ASA between opportunity and crisis – Your profit strategy